Interestingly, cyclization of the peptide improved very significantly its capacity to bind to FOXP3, to inhibit Treg in vitro, and more importantly, to delay tumor growth in combination with anti-PD1 antibodies in a model of hepatocellular carcinoma. Here, FOXP3 is linked to neoplasm.